Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2+1 dosing regimen

References

• Hu T, Weiss T, Bencina G, et al. Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries. J Med Econ. 2021 Jan;24(1):1098–1107. eng. doi: 10.1080/13696998.2021.1970975
   PubMed Web of Science ®Google Scholar
• Savulescu C, Krizova P, Valentiner-Branth P, et al. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: spidnet observational multicentre study. Vaccine. 2022 Jun 23;40(29):3963–3974. doi: 10.1016/j.vaccine.2022.05.011
   PubMed Web of Science ®Google Scholar
• Izurieta P, Bahety P, Adegbola R, et al. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution. Expert Rev Vaccines. 2018 Jun;17(6):479–493. doi: 10.1080/14760584.2018.1413354
   PubMed Web of Science ®Google Scholar
• Invasive pneumococcal disease – annual epidemiological report for 2017 September 7. 2023. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2017-invasive-pneumococcal-disease.pdf
   Google Scholar
• Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018 Jul;6(7):e744–e757.
   PubMed Web of Science ®Google Scholar
• Hu T, Weiss T, Bencina G, et al. Comprehensive value assessments for new pediatric pneumococcal conjugate vaccines. J Med Econ. 2021 Jan;24(1):1083–1086.
   PubMed Web of Science ®Google Scholar
• European centre for disease prevention and control. Surveillance atlas of infectious diseases; 2020 [cited 2023 Sep 7]. Available from: https://atlas.ecdc.europa.eu/public/index.aspx
   Google Scholar
• Balsells E, Guillot L, Nair H, et al. Serotype distribution of streptococcus pneumoniae causing invasive disease in children in the post-pcv era: a systematic review and meta-analysis. PloS One. 2017;12(5):e0177113. doi: 10.1371/journal.pone.0177113
   PubMed Web of Science ®Google Scholar
• Mungall BA, Hoet B, Nieto Guevara J, et al. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. Expert Rev Vaccines. 2022 Feb;21(2):201–214. eng. doi: 10.1080/14760584.2022.2012455
   PubMed Web of Science ®Google Scholar
• Wasserman MD, Perdrizet J, Grant L, et al. Clinical and economic burden of pneumococcal disease due to serotypes contained in current and investigational pneumococcal conjugate vaccines in children under five years of age. Infect Dis Ther. 2021 Dec;10(4):2701–2720. eng. doi: 10.1007/s40121-021-00544-1
   PubMed Web of Science ®Google Scholar
• Ryman J, Weaver J, Hu T, et al. Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data. NPJ Vaccin. 2022 Nov 7;7(1):140. doi: 10.1038/s41541-022-00538-1
   PubMed Web of Science ®Google Scholar
• Lee J. Pneumococcal conjugate vaccines: Choice of schedule and product development. Clin Exp Pediatr. 2020 Jul;63(7):259–260. doi: 10.3345/cep.2019.01739
   PubMedGoogle Scholar
• Ryman J, Weaver J, Yee KL, et al. Predicting effectiveness of the v114 vaccine against invasive pneumococcal disease in children. Expert Rev Vaccines. 2022 Oct;21(10):1515–1521. doi: 10.1080/14760584.2022.2112179
   PubMed Web of Science ®Google Scholar
• Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007 May 10;25(19):3816–3826. doi: 10.1016/j.vaccine.2007.01.119
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014 Sep;14(9):839–846. doi: 10.1016/S1473-3099(14)70822-9
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Porat N, et al. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial. Vaccine. 2012 Jul 20;30(34):5132–5140. doi: 10.1016/j.vaccine.2012.05.059
   PubMed Web of Science ®Google Scholar
• Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med. 1980 Sep 4;303(10):549–552.
   PubMed Web of Science ®Google Scholar
• A study of v419 given concomitantly with Prevnar 13™ and rotateq™ (v419-006). Clinicaltrials.Gov id: Nct01340937 [cited 2022 Feb 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT01340937
   Google Scholar
• Mussi-Pinhata MM, Ward S, Laimon L, et al. Effect of maternal immunization with 10-valent pneumococcus conjugate vaccine (pcv-10), 23-valent pneumococcus polysaccharide vaccine, or placebo on the immunogenicity of pcv-10 in human immunodeficiency virus-exposed uninfected infants: a randomized clinical trial. Clin Infect Dis. 2022 Sep 29;75(6):996–1005. doi: 10.1093/cid/ciac026
   PubMed Web of Science ®Google Scholar
• Safety, tolerability, and immunogenicity of v114 in healthy infants (v114-025) (pneu-ped-eu-1). Clinicaltrials.Gov Id: Nct04031846 [cited 2023 Aug 11]. Available from: https://clinicaltrials.gov/study/NCT04031846?term=NCT04031846&rank=1
   Google Scholar
• Safety, tolerability, and immunogenicity of a 3-dose regimen of v114 in healthy infants (pneu-ped-eu-2/v114-026) (pneu-ped-eu-2). Clinicaltrials.Gov id: Nct04016714 [cited 2023 Aug 11]. Available from: https://clinicaltrials.gov/study/NCT04016714?term=NCT04016714&rank=1
   Google Scholar
• 20-valent pneumococcal conjugate vaccine safety and immunogenicity study of a 3-dose series in healthy infants. Clinicaltrials.Gov id: Nct04546425 [cited 2023 Sep 5]. Available from: https://www.clinicaltrials.gov/study/NCT04546425?term=nct04546425&rank=1
   Google Scholar
• Nolan KM, Zhang Y, Antonello JM, et al. Enhanced antipneumococcal antibody electrochemiluminescence assay: validation and bridging to the who reference elisa. Bioanalysis. 2020 Oct;12(19):1363–1375.
   PubMed Web of Science ®Google Scholar
• Tan CY, Immermann FW, Sebastian S, et al. Evaluation of a validated luminex-based multiplex immunoassay for measuring immunoglobulin g antibodies in serum to pneumococcal capsular polysaccharides. mSphere. 2018 Aug 8;3(4):e00127–18. eng. doi: 10.1128/mSphere.00127-18
   PubMed Web of Science ®Google Scholar
• Ryman J, Sachs JR, Yee KL, et al. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines v114 and pcv20 against invasive pneumococcal disease in children. Expert review of vaccines. Expert Rev Vaccines. 2024 Jan;23(1):60–68. doi: 10.1080/14760584.2023.2292773
   PubMed Web of Science ®Google Scholar
• Jodar L, Butler J, Carlone G, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine. 2003 Jul 4;21(23):3265–3272. doi: 10.1016/S0264-410X(03)00230-5
   PubMed Web of Science ®Google Scholar
• Assessment report: Prevenar 20 the Netherlands: European Medicines Agency; 2024 [cited 2024 Mar 21]. Available from: https://www.ema.europa.eu/en/documents/variation-report/prevenar-20-previously-apexxnar-h-c-005451-ii-0012-epar-assessment-report-variation_en.pdf
   Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 2016 May;4(5):399–406. doi: 10.1016/S2213-2600(16)00052-7
   PubMed Web of Science ®Google Scholar
• Jokinen JT, Ahman H, Kilpi TM, et al. Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J Infect Dis. 2004 Aug 1;190(3):545–550. doi: 10.1086/422531
   PubMed Web of Science ®Google Scholar
• Voysey M, Fanshawe TR, Kelly DF, et al. Serotype-specific correlates of protection for pneumococcal carriage: an analysis of immunity in 19 countries. Clin Infect Dis. 2018 Mar 5;66(6):913–920. doi: 10.1093/cid/cix895
   PubMed Web of Science ®Google Scholar